Hosted on MSN1mon
Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion
Novartis agreed to acquire Blackstone Life Sciences’ Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline. The deal means the Swiss pharmaceutical company ...
MM&M1mon
Novartis buys back Anthos Therapeutics for up to $3.1B
Novartis has gone full circle with Anthos Therapeutics. The Swiss pharma giant is doubling down on its expertise in the cardiovascular area by acquiring the clinical-stage biotech firm mostly owned by ...
Why Novartis Remains A 'Buy' After Beating Expectations Again
Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...
Pharm Exec29d
Novartis Strikes Deal to Acquire Anthos Therapeutics
Novartis announced that it has agreed to terms to acquire Anthos Therapeutics for an upfront payment of $925 million. The deal will include abelacimab, a Factor XI-inhibiting monoclonal antibody in ...
Business Times1mon
Novartis to acquire Anthos for up to US$3.1 billion
Swiss pharmaceutical giant Novartis said on Tuesday (Feb 11) it has agreed to acquire biopharma firm Anthos Therapeutics for up to US$3.1 billion. Anthos was founded by Blackstone Life Sciences and ...
PMLiVE1mon
Novartis to expand cardiovascular pipeline with $3.1bn Anthos acquisition
Novartis has announced that it will be expanding its late-stage cardiovascular pipeline by acquiring Anthos Therapeutics for approximately $3.1bn. The deal gives Novartis access to abelacimab, which ...
AFP1mon
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI ...
pharmaphorum4d
Versant, Novartis team up again in hunt for another Chinook
Novartis has agreed to buy Anthos from private equity firm Blackstone for $3.1 billion, taking Factor XI inhibitor abelacimab back in-house.
Seeking Alpha26d
Novartis: Strong Execution With A P/E Discount
Q4 2024 results exceeded expectations with 16% net sales growth and a 55% increase in operating income, supporting Novartis' EPS growth trajectory. The acquisition of Anthos Therapeutics and ...
Benzinga.com16d
Court Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program
Also Read: Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal For over 30 years, Congress has imposed price ceilings on prescription drugs ...
The Boston Globe1mon
SEC moves to kill climate disclosure rule
BLOOMBERG NEWS Swiss pharmaceutical giant Novartis announced on Tuesday the purchase of Cambridge-based biopharma firm Anthos Therapeutics for $925 million upfront. The deal, which is expected to ...